{"links":{"html":"https://www.erudio.com/reports/radian-nct05784012","json":"https://www.erudio.com/reports/radian-nct05784012.json","markdown":"https://www.erudio.com/reports/radian-nct05784012.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"radian-05784012"}},"request":"https://www.erudio.com/contact?report=radian-05784012"},"offer":{"cited_commentary_sources":8,"verified_hcp_statements":19,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":2,"optional":true,"price_per_verified_person_usd":15,"price_usd":30,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"radian-nct05784012"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=radian-05784012","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/radian-nct05784012","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:47:21.811570Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: 1-year disease free survival"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":1,"coverage":"discussed","id":"A1","source_count":1,"title":"Perceived standard-of-care impact"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Academic independence and cooperative-group research value"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":1,"title":"PRIME: separate surgery-directed experience with niraparib and dostarlimab"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"interpretation":5,"opinion":6,"primary_context":2,"restatement":5,"unspecified":1},"claims_by_kind":{"attributed_opinion":5,"protocol_statement":2,"source_observation":12},"clinician_statements":5,"evidence_units":10,"findings":4,"organisational_accounts":1,"people_cited":4,"people_identity_verified":2,"people_total":4,"screened_sources":29,"verified_claims":19},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":1,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"A speaker's principal concern is prolonged radiotherapy toxicity in cisplatin-unfit cohort B"},{"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":6,"sources_by_kind":{"commentary":5,"registry":1}},"title":"A speaker's encouragement supports continued evaluation in cisplatin-fit cohort A"},{"id":"F3","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":1,"support":1},"ma_question":false,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"The standard-of-care impact rating is categorical but unexplained"},{"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":4,"links":{"context":1,"support":3},"ma_question":false,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Praise centers on academic evidence generation and the research effort"}],"medical_affairs_question":"What cohort-specific evidence would distinguish continued research from a justified practice-change assessment while addressing the reported harm?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Cohort B: reported harm is population- and schedule-specific"},{"id":"section-2","level":2,"title":"Cohort A: encouragement means further evaluation, not adoption"},{"id":"section-3","level":2,"title":"Practice impact: a rating without a rationale"},{"id":"section-4","level":2,"title":"Academic research earns praise, not a treatment endorsement"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2}],"id":"T1","label":"Primary endpoint: 1-year disease free survival"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:47:21.811570Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T06:26:27Z","record_hash":"39ad95d927b298e82d86a48ea5c0df9c852edb54b0611d41360047283a7be943","release_hash":"ea40f5342ca1298a408dc1c1f7d6ade13af902ac8e1e3961957489d7ae2fe8a7","report_id":"erudio-nct05784012","run_id":"43eae007-d598-4bd8-8952-24725bb27ae6","schema_version":"5.0","slug":"radian-05784012","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"RADIAN asks whether adding niraparib and dostarlimab to definitive radiotherapy, with or without cisplatin, improves outcomes in locally advanced head and neck squamous cell carcinoma. Whether further evaluation will support routine adoption remains open. A LinkedIn speaker, described in the source as scientific coordinator of the trial’s sponsor, welcomes further evaluation in cisplatin-fit patients. A radiation oncologist raises radiotherapy-toxicity concerns in cisplatin-unfit patients. One X account’s practice-impact rating is unexplained. The sources reviewed for this edition place the trial’s main results at ESMO 2026.","meta_description":"29 sources screened · 19 verified statements (5 from clinicians verified by NPI or staff page) from 9 sources · 4 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-d7bb3f82284975f4e344","claim-f3ccbe9dcfbe837c759f","claim-c15063790284cc90e4da"],"id":"F1","paraphrase":"An X thread addresses how radiotherapy safety and disease-free survival should be evaluated together in RADIAN.","publication_caveats":{"reason":"No publication caveats are specified.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-24","title":"A speaker's principal concern is prolonged radiotherapy toxicity in cisplatin-unfit cohort B"},{"cited_claim_ids":["claim-13bf21407038b6119023"],"id":"F3","paraphrase":"An X post addresses whether RADIAN could change standard treatment.","publication_caveats":{"reason":"No publication caveats are specified.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-25","title":"The standard-of-care impact rating is categorical but unexplained"}]},"publication":{"approved_at":"2026-10-29T06:26:27Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":29},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed are not a representative sample of HCP opinion. Multiple closely overlapping posts by one author do not establish consensus or independent confirmation.","Discussion using unnamed trial references, alternative wording or transcription variants may be missing. Many sources without explicit trial naming were not read, and one additional X discussion was not fully assessed for clinician views.","No full RADIAN protocol or exact-trial results publication was available among the sources reviewed. Historical comparability, statistical uncertainty and detailed safety cannot be independently evaluated here.","Exact product-label documents for dostarlimab and cisplatin plus radiotherapy were unavailable; this report draws no regulatory conclusion.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","PRIME comments concern a separate neoadjuvant, surgery-directed study. They cannot establish efficacy, safety or patient-selection rules for RADIAN's definitive-radiotherapy setting."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":6,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":8,"methods":1},"count":9,"evidence_window":{"end":"2026-10-25","start":"2025-11-19"},"retrieval_snapshot":"2026-10-28T21:46:55.830944Z","timeline":[{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W23"},{"count":6,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05784012:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05784012:context","quote_policy":"short_quote_link_out"},{"id":"openfda:b7f675e2-159c-490c-b6f4-3f16d9492b7d:20260728","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ysesz2mn5ig5vitaq3qdjos-3myryv2rfep24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3myrymqbwhs2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-wh5xpwynddn5z3ct4zrpe65i-3lcmvpki7z222","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-yop6e6r3on7tkvs5mnfwr7yp-3ld7cloop4s27","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7468612172915388416","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:465b94","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5fa930","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1115074786756124672:cf7b3fd7-f6ed-4481-a922-b1776f7d6237","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1623730055149981702:c9aafafe-e604-40fb-b2d8-1baef7c9d72d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1640784821826756610:2057d843-7db6-4a0f-9e75-222715846440","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1641991195843784706:6f04f7ed-dbe8-4a54-874c-a6bc0f2574d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027068884495581438:730fd7b0-2b63-4b20-9512-ec742e3de9de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060369408975892910:971f0f84-6a2e-48ce-9e34-b38b586c81d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114127076848500861:0dd033bb-0858-4a34-887b-a08d863d7282","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114127254846341416:02ace1d5-8e3a-4161-82b3-98a5d58f7493","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114136682953843089:49ee12a7-82f7-4428-b8a7-6a311e7c3ea7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114136795147538782:a95b54a1-8d9f-4c6d-a4b6-77b3d967d35e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114266127312536060:33ad769e-f683-45db-b29f-a18036ddfa01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114372559084941421:7a5eadd4-b32c-48f3-bc09-98a437e8d50a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114734805644431466:25be928d-1f33-40cd-9596-e0b6892ac395","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114735821781663959:bf80abed-ccff-4cff-a74f-76520b61547c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115121854436327897:f8ce5caa-4c7f-49b3-8eb0-249029a92e51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2099758412514947422","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0XfrF6V1Kro","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:CY37DOXpGF4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jnab5Lr_D4I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mVwIm9gYaSQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:rmLefzZG6NQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ro9sZtXrvVM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":1,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":1,"youtube":6},"by_evidence_role":{"commentary":29},"count":29,"evidence_window":{"end":"2026-10-27","start":"2019-04-08"},"retrieval_snapshot":"2026-10-28T21:46:56.799415Z","timeline":[{"count":1,"week":"2019-W15"},{"count":1,"week":"2020-W25"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2023-W06"},{"count":2,"week":"2023-W13"},{"count":1,"week":"2023-W17"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W38"},{"count":6,"week":"2026-W43"},{"count":5,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Jemperli"],"label":"dostarlimab","slug":"dostarlimab"},{"reason":"Unmapped registry intervention: niraparib","status":"unmapped"},{"reason":"Unmapped registry intervention: cisplatin plus radiotherapy","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Head and Neck Squamous Cell Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"RADIAN","aliases":["RADIAN","Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma"],"brief_title":"Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","collaborators":["GlaxoSmithKline","MFAR"],"conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":{"count":34,"type":"ACTUAL"},"interventions":[{"name":"Dostarlimab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Niraparib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"cisplatin plus radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Niraparib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05784012","official_title":"Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_endpoints":[{"description":"Disease-free survival (DFS) is defined as the time from the date of study treatment initiation to the date of first record of any of the following events: Investigator determined: Locoregional progression or recurrence. Distant metastasis. Neck dissection or surgery performed for clinical or radiological disease progression (RECIST 1.1) \\> 20 weeks from the end of radiation therapy with tumor present on final pathology. Death due to any cause. Patients not presenting any of the previous events will be censored at the date of last assessment.","measure":"1-year disease free survival","timeFrame":"1 year after the start of the study treatment"}],"registry_last_updated":"2026-06-04","registry_url":"https://clinicaltrials.gov/study/NCT05784012","short_name":"RADIAN","short_name_basis":"registry_acronym","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","start_date":{"date":"2023-11-13","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1, phase2","study_ids":[{"id":"TTCC-2022-01-RADIAN","type":"sponsor_study_id"},{"id":"2024-516779-33-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}